Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study-Reference-Cited by-同舟云学术

Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study

Published:2001-12 Issue: Volume:34 Page:77-80
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Agelaki Sophia,Bania Helen,Kouroussis Charalambos,Blazoyiannakis George,Souglakos John,Tsiafaki Xanthi,Kalbakis Kostas,Rapti Ageliki,Androulakis Nikos,Georgoulias Vassilis,Papadakis Emmanuel

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised trials;Br. Med. J.,1995

2. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer;Fossela;J. Clin. Oncol.,1995

3. Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer;Santoro;Lung Cancer (Abstract),1994

4. Vinorelbine as a single agent in the treatment of advanced non-small cell lung cancer;Rinaldi;Proc. Am. Soc. Clin. Oncol. (Abstract),1994

5. Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients;Pronzato;Anticancer Res.,1994

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non–Small-Cell Lung Cancer Pretreated With Non–Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study;Clinical Lung Cancer;2011-03

2. Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment;Lung Cancer;2008-05

3. A Phase II Trial of Carboplatin/Vinorelbine with Pegfilgrastim Support for the Treatment of Patients with Advanced Non-small Cell Lung Cancer;Journal of Thoracic Oncology;2007-06

4. Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?;Journal of Thoracic Oncology;2006-09

5. Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?;Journal of Thoracic Oncology;2006-09